anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety and effectiveness of PROTONIX I.V. for the treatment of GERD and a history of EE for up to 7 days have been established in pediatric patients 3 months of age and older. Use of PROTONIX I.V. for this indication is supported by evidence from adequate and well-controlled studies of intravenous and oral pantoprazole sodium in adults and oral pantoprazole sodium in pediatric patients, with additional pharmacokinetic and safety data of intravenous pantoprazole in pediatric patients 1 year of age and older and oral pantoprazole in pediatric patients 3 months of age and older. Adverse reactions were generally similar to those reported in adults with intravenous or oral pantoprazole sodium [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].

The safety and effectiveness of PROTONIX I.V. have not been established in patients less than 3 months of age for the treatment of GERD and a history of EE. 

The safety and effectiveness of PROTONIX I.V. have not been established in pediatric patients for the treatment of pathological hypersecretory conditions including ZE syndrome.

Animal Toxicity Data

In neonatal/juvenile animals (rats and dogs) toxicities were similar to those observed in adult animals, including gastric alterations, decreases in red cell mass, increases in lipids, enzyme induction and hepatocellular hypertrophy. An increased incidence of eosinophilic chief cells in adult and neonatal/juvenile rats, and atrophy of chief cells in adult rats and in neonatal/juvenile dogs, was observed in the fundic mucosa of stomachs in repeated-dose studies. Full to partial recovery of these effects were noted in animals of both age groups following a recovery period.
The invention relates to an artificial oil body and a method for manufacturing the same. Primarily, the artificial oil body comprises a mixed liquid of non-triglyceride oils, phospholipids, caleosin and sodium phosphate buffer solution. The mixed liquid is oscillated by an ultrasonic oscillator and soaked with ice. Then the operations of the oscillation and the soaking with ice are repeated. Thereby the artificial oil body is dispersed in an aqueous phase. In particular, a composite solvent is used as oil. It can design the content of the formula for a specific hydrophobic drug to improve its solubility. Furthermore, the particle size of the new type artificial oil body can be smaller and more stable than the droplet size of the natural oil body or the conventional artificial oil body. Moreover, non-DOGP phospholipids can also be used to manufacture the artificial oil body. Therefore, the artificial oil body has the broader formulation flexibility to meet the requirement of portable transfer for various compounds.
CTEPH is a disease that causes progressive pulmonary hypertension due to stenoses or occlusions in the pulmonary artery due to an organized thrombus. And this is a disease that results in right heart failure and death unless early diagnosis and appropriate treatment are performed. Pulmonary endarterectomy (PEA), which surgically removes the intimal thrombus, has been established as the treatment of choice for CTEPH. In the AHA/ACC guideline and ESC guideline, PEA for CTEPH is class IC (1). In 2014, a soluble guanylate cyclase stimulant (generic name: riociguat), which is one of the therapeutic agents for pulmonary hypertension, was approved for patients with CTEPH who are ineligible for PEA, and residual pulmonary hypertension after PEA (2). In addition, it has been reported that BPA, which is a catheter interventional treatment, is also effective to improve hemodynamics in inoperable patients with CTEPH (3, 4). However, some patients have residual symptoms such as dyspnea on exertion even after normalization in hemodynamics by BPA. A randomized control study should be done to confirm the necessary of continuation of riociguat for such patients.
A microneedle patch is described that can be used for the sustained delivery of therapeutic agents into living tissue (e.g., skin). The polymer (gelatin methacryloyl (GelMA)) patch can adjust delivery rates based on the degree of crosslinking. The anticancer drug Doxorubicin (DOX) was loaded into GelMA microneedles using a molding fabrication technique. The GelMA microneedles efficiently penetrated the stratum corneum layer of a mouse cadaver skin. Mechanical properties and therapeutic agent release behavior of the GelMA microneedles can be adjusted by tuning the degree of crosslinking. The efficacy of the DOX released from the GelMA microneedles was tested and demonstrated the anticancer efficacy of the released drugs against melanoma cell line A375. Because GelMA is versatile material in engineering tissue scaffolds, GelMA microneedles can be used as a platform for the delivery of various types of therapeutic agents to tissue.
PROBLEM TO BE SOLVED: To obtain a cosmetic stock having skin beautifying effect as well as being safe when applied to the skin, by using an extract afforded by subjecting Rooibos tea leaves to extraction with a specific solvent. SOLUTION: This cosmetic stock is obtained by using an extract from Rooibos tea leaves. The extract is afforded by subjecting Rooibos tea leaves to extraction using a solvent selected from water and hydrophilic solvents (pref. water or a hydrous organic solvent, esp. pref. water or a mixed solvent of water and ethanol). The tea leaves for extraction is prepared by drying leaves of Aspalathus linealis or Aspalathus cedarbergensis, or by chopping the leaves followed by roasting. The extract is usable either directly as liquid extract or in the form of powder obtained by lyophilizing the liquid extract.
The present invention relates to a Chinese patent medicine for treating epilepsy. Epilepsy is a stubborn disease which is hard to radically treat, and the existing effects of traditional and western medicines for treating epilepsy are not ideal. The Chinese patent medicine is based on the treating principle of treating epilepsy, extinguishing wind, eliminating phlegm for resuscitation, clearing heart fire and activating blood circulation to dissipate blood stasis. The oral Chinese patent medicine is prepared from centipede, scorpion, stiff silkorm, earthworm, red sage root, safflower, gastrodia tuber, grassleaf sweetflag rhizome, bile arisaema, alum and calculus bovis. The prescription can not only consider the control of acute phase symptoms of epilepsy, but also have the function of strengthening treating effects, and the purpose of treating both manifestation and root causes of diseases can be obtained. The clinical effective rate is 91%, and the Chinese patent medicine has the advantages of small toxic or side effects, safe and reliable performance and low price, and the Chinese patent medicine is easy to receive by patients.
PURPOSE:To obtain an antioxidant which has a good antioxidant power, is nontoxic without polluting the environment, and is odorless and tasteless without giving an gueer taste by using a specific phenoxyalkanoic acid or its salt as the effective component. CONSTITUTION:This antioxidant contains, as the effective component, a phenoxyalkanoic acid of the formula (wherein R is H, a halogen, hydroxyl, a lower alkyl, a lower alkanoyl, or a lower alkoxy; (n) is 0-4; and A is a 1-8C linear or branched alkylene) or its salt. Esp. pref. examples are phenoxyacetic, 2-phenoxypropionic, 2-phenoxybutyric, and 2-(p-methoxyphenoxy)propionic acids. The acid or its salt is synthesized by a known method, e.g. condensation, and is used generally in an amt. of 0.000001-10 pts.wt. based on 100 pts.wt. oxidizable substance.
1,274,820. Newcastle disease virus. TAKEDA YAKUHIN KOGYO K.K. 27 Nov., 1970 [29 Nov., 1969], No. 56463/70. Heading A5B. A method of producing an attenuated Newcastle disease vaccine comprises: (1) cultivating Newcastle disease virus either by at least 20 serial passages in a porcine tissue culture or for at least 2 months in porcine stable cell lines to produce porcine cells containing attenuated virus, (2) inoculating this on to the chorioallantoic membrane of a chick embryo and cultivating the chick embryo and (3) recovering the virus from the resulting complex of chorioallantoic membrane and porcine cells and subjecting it to at least 2 serial passages in the allantoic cavity of a chick embryo. The procine tissue culture may contain primary kidney cells. Step (1) may be carried out by persistent infection of porcine stable cell lines with the virus. The virus recovered in step (3) may be further cultivated in a culture containing chick embryo cells to produce the vaccine.
Revised idiopathic pulmonary fibrosis treatment guidelines were published in 2015, and nintedanib was conditionally recommended. Although diarrhea is reported to be a common major adverse event associated with nintedanib, there have been few reports on detailed endoscopic findings of nintedanib-associated enterocolitis. A 74-year-old woman was diagnosed with idiopathic pulmonary fibrosis 4 years ago in May. She was started on nintedanib (300 mg). Three months later, hepatic dysfunction was observed; therefore, the drug was temporarily discontinued and then resumed at a dose reduction of 200 mg. Five months later, the patient developed diarrhea, and the dose was reduced to 150 mg. However, no effect was noted; hence, colonoscopy was performed. Various inflammatory lesions, such as erythema and erosions, were observed continuously at the rectum, which resembled ulcerative colitis. No improvement was observed 2 months after follow-up colonoscopy, and nintedanib-related enterocolitis was suspected. The dose was further reduced to 100 mg. Since the endoscopic findings of nintedanib-associated enterocolitis are similar to those of ulcerative colitis, it is critical to consider patients with diarrhea who are taking nintedanib as having associated enterocolitis and attempt to reduce or discontinue the drug if diarrhea does not improve with antidiarrheal agents.
The invention discloses a healthy decoction for treating lower extremity atherosclerotic occlusive disease. The decoction is characterized by comprising the following components in parts by weight: 25-30 parts of radix clematidis, 25-30 parts of lycopodium clavatum, 15-20 parts of parasitic loranthus, 15-20 parts of Chinese angelica, 15-20 parts of salviae miltiorrhizae, 15-20 parts of suberect spatholobus stem, 10-15 parts of angelica root, 12-16 parts of gentiana macrophylla, 12-16 parts of hematoxylon, 12-16 parts of notopterygium root, 12-16 parts of radix angelicae pubescentis, 3-5 parts of safflower and 3-5 parts of dried ginger. The raw materials are decocted with water, the decoction dregs are taken out, and the decoction is cooled and packaged in bags. A proper amount of hot water is added into the decoction for leg bathing when the decoction is used. The decoction holds the traditional Chinese medical principle that treatment mainly concerns the position that channels pass, and the traditional Chinese medicinal acupoints on legs are stimulated by a method for bathing legs by decoction. The decoction has the effects of dredging meridians and activating blood, promoting blood circulation to remove stasis, diminishing swelling and relieving pain and the like, and has a remarkable effect for treating lower extremity atherosclerotic occlusive disease.
The present invention relates to a traditional Chinese medicine product whose crystal water is not removed by calcined alum. The present invention is characterized in that if the product is applied to a small and shallow cut, blood can be stopped within half a minute in most cases; the cut shrinks and scabs only by stabilization of 8 minutes, and the product resists water. Disinfection and wrapping are not needed, and infection sources are stopped. Therefore, inflammatory reaction is relieved. Work or housework is not influenced, and most indication is cured after 1 to 2 weeks. After being applied to a small and shallow cut, the existing products, such as jindaosan, Yunnan white drug-powder, etc., can stop blood within 1 minute in most cases; the cut shrinks and scabs after 2 to 4 days and needs to avoid water for 3 to 6 days; disinfection and wrapping are needed, and infection sources are not stopped. Therefore, inflammatory reaction is not relieved, and work, housework, etc. are influenced.
Three intravitreal injections at 1.0 milligram per eye each 28 days apart will be administered to the study eye. Participants will be followed for 84 days total.
FIELD: food industry. ^ SUBSTANCE: invention relates to food industry. A water-dispersible granulate has average weighted weight diameter at least 100 mcm, preferably at least from 200 mcm and up to 2000 mcm. The said granulate contains: 40-90 wt % of carbohydrates; 2-30 wt % of lipids containing unsaturated fatty acids in an amount of at least 1%, preferably no less than 3% of the granulate weight and at least 30 mg/kg - 800 mg/kg of a metal enhancing oxidation and selected from the group consisting of ferrum, cuprum and their combinations wherein at least 50 wt %, preferably at least 70 wt % of lipids are present in the form of undispersed lipids. ^ EFFECT: invention allows to produce a granulate resistant to oxidation the production method whereof is implemented under mild conditions. ^ 18 cl, 6 tbl, 3 ex
Structural variations involving enhancer hijacking induce aberrant oncogene expression and cause tumorigenesis. A rare translocation, t(3;8)(q26.2;q24), is associated with MECOM and MYC rearrangement, causing myeloid neoplasms with a dismal prognosis. The most recent World Health Organization classification recognises myeloid neoplasms with MECOM rearrangement as acute myeloid leukaemia (AML) with defining genetic abnormalities. Recently, the increasing use of induced pluripotent stem cell (iPSC) technology has helped elucidate the pathogenic processes of haematological malignancies. However, its utility for investigating enhancer hijacking in myeloid neoplasms remains unclear. In this study, we generated iPSC lines from patients with myelodysplastic syndromes (MDS) harbouring t(3;8)(q26.2;q24) and differentiated them into haematopoietic progenitor cells to model the pathophysiology of MDS with t(3;8)(q26.2;q24). Our iPSC model reproduced the primary patient's MECOM expression changes and histone H3 lysine 27 acetylation (H3K27ac) patterns in the MECOM promoter and MYC blood enhancer cluster (BENC). Furthermore, we revealed the apoptotic effects of the bromodomain and extra-terminal motif (BET) inhibitor on iPSC-derived MDS cells by suppressing activated MECOM. Our study demonstrates the usefulness of iPSC models for uncovering the precise mechanism of enhancer hijacking due to chromosomal structural changes and discovering potential therapeutic drug candidates for cancer treatment.
The 25-item retrospective Childhood Trauma Questionnaire (CTQ) will be administered to assess history of abuse and neglect. The CTQ measures five types of maltreatment: emotional, physical, and sexual abuse and emotional and physical neglect.
We evaluated the possibility of treatment-free remission (TFR) and durability of deep molecular response (DMR) with asciminib treatment by monitoring major BCR::ABL mRNA on the International Scale (BCR::ABL-IS) in 4 patients who needed to reduce or discontinue asciminib due to adverse event concerns, intolerance, or personal circumstances. IS increased in all 4 patients after discontinuation of asciminib, but 3 patients who resumed asciminib achieved DMR again. None of the patients achieved TFR with asciminib, but DMR could be achieved again by restarting asciminib after TFR failure. As this was a retrospective study in a small number of patients, no conclusions can be drawn regarding the possibility of TFR with asciminib. However, this study included patients with short treatment duration and DMR maintenance periods, so strict conditioning may be necessary. Safe dose reduction or TFR with asciminib may need to be considered in more cases.
Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
Low energy availability is a situation triggered by a low energy intake relatively to the total energy needs. It may typically occur when energy expenditure is increased by sporting activities concurrently to an unconscious or voluntarily insufficient increase in energy intake. This may cause a condition called Relative energy deficiency in sport (RED-s), indicating a high risk for several negative health effects and performance deterioration. Athletes competing in body weight sensitive sports or sports categorized by body weight, have been identified with higher prevalence of RED-s, and specifically young females. Although it is the total difference between energy needs and energy availability that causes such scenario, the methods used to regulate body weight do also matter. Athletes without proper guidance on nutritional needs, recovery strategies, and optimal body weight regulation have previously reported use of harmful dieting methods, like purging methods, dehydration methods, and use of pharmaceuticals. Thus, young females competing in weight sensitive sport, not receiving any professional health and performance coaching are at specific risk for acutely and longterm negative health effects from chronic or repeated cycles of body weight reduction.

In a rapidly expanding martial arts industry in the US, there have been several reports on sexual assault. Still, no systematic and first-hand documentation on this issue has been completed. In Norway the same increase in popularity of material arts are noticed, an interest also seen among females. With regards to the limited knowledge on exercise practice, eating routines and health symptoms in female material art athletes, this study aims to expand this. By relying on a cross sectional cohort design with systematic registration of outcomes, this study also aim to expand on current limited knowledge on experiences of sexual harassment among females in material arts.

All females aged 16-35 practicing material arts in Oslo (Norway) at the time of recruitment (september-december 2020) will be invited (estimated to be between 200-300 athletes). All participants will receive information on the aim of this study, and must sign informed consent before participation. All data will be measured once per athlete.
INTRODUCTION: The impact of young child formula (YCF) consumption on children's growth, particularly under suboptimal conditions, has scarcely been studied. In the current study, weight-for-age (WAZ), length-for-age (LAZ), and BMI-for-age (BAZ) z-score development was evaluated in children from five different countries (n = 668) who participated in a double-blind, randomized, controlled trial.
METHODS: The children (1-3 years old) were randomized to one of two intervention YCFs (with presence or absence of prebiotics and n-3 LCPUFAs) during 52 weeks of intervention. Additional stratified analyses evaluated the growth patterns of underweight, overweight, or stunted children.
RESULTS: No apparent differences in anthropometric measurements were observed between the intervention groups. In both YCF intervention groups, mean WAZ, LAZ and BAZ development was indicative of adequate growth during the intervention period. Stratified analyses showed stable WAZ and BAZ development among children with a healthy weight or overweight at baseline. Among underweight and stunted children, normalization in mean weight (∼1 SD) and length (∼0.8 SD) gain, respectively, was observed.
CONCLUSION: The current study suggests that consumption of YCF, either or not containing prebiotics and n-3 LCPUFAs, is associated with adequate growth among young children. This association may depend on the child's baseline nutritional status. Future studies to assess the potential role of YCF in supporting adequate weight/length gain among children at risk for undernutrition are warranted.
NEW MATERIAL:A halogen derivative of myeloperoxidase (when the halogen isI, the characteristics are as follows: Optimal pH: 8.5-8.8. Stable pH: 4-10. Substrate specificity: Reaction with hydrogen peroxide to produce hydrohalogenous ions). EXAMPLE:Iodinated myeloperoxidase. USE:A remedy for microbism, e.g. sepsis or miliary tuberculosis, of mammals having the germicidal action. PROCESS:A halogen salt, e.g. an alkali metallic salt, is added to an aqueous solution of myeloperoxidase, and subjected to the coordination in equimolar amounts to give the aimed halogen derivative of myeloperoxidase. The reaction temperature is 0-30 deg.C. The presence of the halogen is essential to the pharmacological activity, and the pharmacological action is exhibited by a small amount of the halogen joined thereto without using the halogen as an additive. Thus, the pharmaceutical can be simplified.
AIM: To evaluate whole-node histogram parameters of blood flow (BF) maps derived from three-dimensional pseudo-continuous arterial spin-labelled (3D pCASL) imaging in discriminating metastatic from benign upper cervical lymph nodes (UCLNs) for nasopharyngeal carcinoma (NPC) patients.
MATERIALS AND METHODS: Eighty NPC patients with a total of 170 histologically confirmed UCLNs (67 benign and 103 metastatic) were included retrospectively. Pre-treatment 3D pCASL imaging was performed and whole-node histogram analysis was then applied. Histogram parameters and morphological features, such as minimum axis diameter (MinAD), maximum axis diameter (MaxAD), and location of UCLNs, were assessed and compared between benign and metastatic lesions. Predictors were identified and further applied to establish a combined model by multivariate logistic regression in predicting the probability of metastatic UCLNs. Receiver operating characteristic (ROC) curves were used to analyse the diagnostic performance.
RESULTS: Metastatic UCLNs had larger MinAD and MinAD/MaxAD ratio, greater energy and entropy values, and higher incidence of level II (upper jugular group), but lower BF10th value than benign nodes (all p<0.05). MinAD, BF10th, energy, and entropy were validated as independent predictors in diagnosing metastatic UCLNs. The combined model yielded an area under the curve (AUC) of 0.932, accuracy of 84.42 %, sensitivity of 80.6 %, and specificity of 90.29 %.
CONCLUSIONS: Whole-node histogram analysis on BF maps is a feasible tool to differentiate metastatic from benign UCLNs in NPC patients, and the combined model can further improve the diagnostic efficacy.
Atherosclerotic plaque in the carotid arteries is responsible for 10 to 15% of all ischemic strokes. The ongoing NINDS-funded CREST-2 multicenter randomized clinical trial is testing whether in the short term (up to 4 years after study entry) procedural revascularization improves stroke prevention above and beyond what can be achieved with intensive medical management of vascular risk factors, especially hypertension and hyperlipidemia. Our proposal is for an observational extension of the CREST-2 clinical trial to test whether revascularization improves stroke prevention in the clinically relevant long term (up to 8 to 10 years). The current application proposes to use a site-less, centralized telephone approach to extend the follow-up of CREST-2 trial participants for assessing the primary study outcome (stroke) for up to 10 years. The average follow-up will increase from between 2-3 years (clinic-based randomized trial) to 7-8 years (observational extension). Each patient will be contacted by telephone at 6-month intervals, and queried regarding all hospitalizations since the last contact. Suspected stroke events will be adjudicated by an expert clinical events committee based on medical record review.